Search Results - "Riesco Martínez, M.C."

424P Could total neoadjuvant therapy (TNT) become a new standard in locally advanced rectal cancer (LARC)? A systematic review and meta-analysis (MA) of TNT vs. standard chemoradiotherapy (CRT) by Martínez, M.C. Riesco, Grávalos, C., Espinosa-Olarte, P., La Salvia, A., Modrego-Sánchez, A., Robles, L., Garcia-Carbonero, R.

Get full text

1188TiP NICE-NEC, a phase II study of platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally advanced or metastatic grade 3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic tract or of unknown origin. GETNE-T1913 by Martínez, M.C. Riesco, Capdevila, J., Alonso, V., Teule, A., Grande, E., Jimenez-Fonseca, P., Benavent, M., Gordoa, T. Alonso, Custodio, A., Carbó, C. Hierro, López, C., García, I. Sevilla, García-Carbonero, R.

Get full text

628PA META-ANALYSIS ON THE EFFICACY OF SECOND LINE (2L) TREATMENT OPTIONS FOR ADVANCED GASTRIC CANCER (AGC) by Riesco Martínez, M.C., Adeva Alfonso, J., Andrés Esteban, E., Gómez-Martín, C., Lema Roso, L., Robles Díaz, L., Parrilla Rubio, L., Ruiz-Ares, G., Pernaut Sánchez, C., López-Martín, J.A.

“…Abstract Aim: Different regimens of systemic chemotherapy (CT) and targeted therapy (TT) have proven to be effective in 2L AGC. No randomized clinical trials…”
Get full text

A Meta-Analysis on the Efficacy of Second Line (2L) Treatment Options for Advanced Gastric Cancer (Agc) by Riesco Martínez, M.C., Adeva Alfonso, J., Andrés Esteban, E., Gómez-Martín, C., Lema Roso, L., Robles Díaz, L., Parrilla Rubio, L., Ruiz-Ares, G., Pernaut Sánchez, C., López-Martín, J.A.

Get full text

496MO Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin by Riesco Martinez, M.C., Capdevila Castillon, J., Alonso, V., Jimenez-Fonseca, P., Teule, A., Grande, E., Sevilla, I., Benavent, M., Alonso-Gordoa, T., Custodio, A., Antón Pascual, B., Hernando, J., Polo, E., Castillo Trujillo, O.A., Garcia-Carbonero, R.

Get full text

595P The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703) by Capdevila Castillon, J., Alonso, V., Macias Declara, I., Melian, M., Gallego Plazas, J., Vera, R., Riesco Martinez, M.C., Maurel, J., Grana Suarez, B., Hernando, J., Garcia Alvarez, A., Navalpotro, B., Soler Gonzalez, G., Polo, E., Garcia Fadrique, A., Espin, E., Fernandez Martos, C., Villacampa Javierre, G., Losa, F.

Get full text

1158MO Metabolomic profile of advanced neuroendocrine cancer patients by Soldevilla, B., Lens-Pardo, A., Lopez-Lopez, A., Carretero-Puche, C., La Salvia, A., Riesco-Martinez, M.C., Espinosa-Olarte, P., López-Gonzálvez, Á., Barbas, C., Garcia-Carbonero, R.

Get full text

1098O Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913) by Riesco-Martinez, M.C., Capdevila, J., Alonso, V., Jimenez-Fonseca, P., Teule, A., Grande, E., Sevilla, I., Benavent Viñuales, M., Alonso-Gordoa, T., Custodio, A., Hernando, J., Polo, E., Castillo Trujillo, O.A., Garcia-Carbonero, R.

Get full text

416P Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01) by Aparicio, J., Manrique, A.C. Virgili, Capdevila, J., Boza, F. Muñoz, Galván, P., Richart, P., Oliveres, H., Paez, D., Hernando, J., Serrano, S. Garcia, Vera, R., Hernandez, X., Gallego, R. Alvarez, Riesco-Martinez, M.C., García de Albeniz, X., Maurel, J.

Get full text

342P A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients by Rodriguez-Ariza, A., Gomez España, M.A., Elez Fernandez, M.E., Gravalos Castro, M.C., García Alfonso, P., Losa, F., Ales Diaz, I.C., Grana Suarez, B., Gallego, I., García-Ortiz, M.V., Polo Marques, E., Salgado Fernandez, M., Rivera Herrero, F., Safont Aguileria, M.J., Salud Salvia, M.A., Ruiz-Casado, A., Tabernero, J., Riesco Martinez, M.C., Toledano-Fonseca, M., Ara Aguilar, E.

Get full text

1164P Prognostic value of miRNA profiling in neuroendocrine neoplasias (NENs) from lung and gastroenteropancreatic (GEP) origin by Espinosa-Olarte, P., Soldevilla, B., Carretero-Puche, C., Molina-Pinelo, S., Robles, C., Benavent, M., Gomez-Izquierdo, L., Morales-Burgo, P., Jimenez-Fonseca, P., Fierro-Fernandez, M., La Salvia, A., Lens-Pardo, A., Riesco-Martinez, M.C., Garcia-Carbonero, R.

Get full text

518P - SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus by De Jesus-Acosta, A., Crespo Herrero, G., Gómez-Dorronsoro, M.L., Alonso, V., Riesco Martinez, M.C., Custodio, A., Lopez, C., Benavent, M., Carmona Bayonas, A., Jimenez-Fonseca, P., Llanos, M., López De San Vicente, B., Arrazubi Arrula, V., Grandez, R., González-Borja, I., Goñi, S., Arozarena, I., Baretti, M., Viudez, A.

“…Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in…”
Get full text

Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: First-in-human clinical trial by Garcia-Carbonero, R., Gil Martín, M., Alvarez Gallego, R., Macarulla Mercade, T., Riesco Martinez, M.C., Guillen-Ponce, C., Vidal, N., Real, F.X., Moreno, R., Maliandi, V., Mato-Berciano, A., Bazan-Peregrino, M., Capella, G., Alemany, R., Blasi, E., Blasco, C., Cascallo, M., Salazar, R.

Get full text

710P - Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: First-in-human clinical trial by Garcia-Carbonero, R., Gil Martín, M., Alvarez Gallego, R., Macarulla Mercade, T., Riesco Martinez, M.C., Guillen-Ponce, C., Vidal, N., Real, F.X., Moreno, R., Maliandi, V., Mato-Berciano, A., Bazan-Peregrino, M., Capella, G., Alemany, R., Blasi, E., Blasco, C., Cascallo, M., Salazar, R.

“…Expression of hyaluronidase from the selective oncolytic adenovirus VCN-01 modifies tumor matrix in pancreatic tumours. Such effect enhances gemcitabine uptake…”
Get full text

SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus by De Jesus-Acosta, A., Crespo Herrero, G., Gómez-Dorronsoro, M.L., Alonso, V., Riesco Martinez, M.C., Custodio, A., Lopez, C., Benavent, M., Carmona Bayonas, A., Jimenez-Fonseca, P., Llanos, M., López De San Vicente, B., Arrazubi Arrula, V., Grandez, R., González-Borja, I., Goñi, S., Arozarena, I., Baretti, M., Viudez, A.

Get full text

The role of antiangiogenic therapy in advanced gastro-esophageal cancer: a systematic review and meta-analysis by Riesco-Martinez, M.C., Díaz-Serrano, A., Gomez-Martin, C., Alfonso, J. Adeva, Cabrera, E. Sabater, Garcia-Carbonero, R.

Get full text

Development and internal validation of a predictive nomogram of progression-free survival in well-differentiated stage IV gastroenteropancreatic neuroendocrine tumours treated with somatostatin analogues: GETNE-TRASGU study by Garcia-Carbonero, R., Alonso, V., Capdevila, J., Sanchez Canovas, M., Alonso, T., Benavent, M., Custodio, A., Crespo Herrero, G., Lopez, C., Hernando, J., Riesco Martinez, M.C., Escudero, P., Gallego Plazas, J., Marazuela, M., Diaz, J.A., Llanos-Munoz, M., La Casta, A., Percovich, J.C., Jimenez-Fonseca, P., Carmona-Bayonas, A.

Get full text

7167 Adjuvant chemotherapy (ACT) in patients with invasive bladder carcinoma (IBC): multivariate analysis of a cohort study by Arija, J.A. Arranz, Beca, R. González, Alvarez, R. Alvarez, López, C. López, Gutiérrez, L. Cabezón, Lovelle, A. Soria, Rodas, I. Márquez, Martínez, M.C. Riesco, Gilarranz, Y. Jerez, Alfonso, J. Adeva

Get full text